Investigational Drug Information for Sulfatinib
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Sulfatinib?
Sulfatinib is an investigational drug.
There have been 17 clinical trials for Sulfatinib.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 7th 2015.
The most common disease conditions in clinical trials are Neuroendocrine Tumors, Neoplasms, and Carcinoid Tumor. The leading clinical trial sponsors are Hutchison Medipharma Limited, Peking University, and Fudan University.
There are four US patents protecting this investigational drug and forty-three international patents.
Summary for Sulfatinib
| US Patents | 4 |
| International Patents | 43 |
| US Patent Applications | 20 |
| WIPO Patent Applications | 17 |
| Japanese Patent Applications | 4 |
| Clinical Trial Progress | Phase 2 (2015-12-07) |
| Vendors | 35 |
Recent Clinical Trials for Sulfatinib
| Title | Sponsor | Phase |
|---|---|---|
| A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | Hutchison Medipharma Limited | Phase 1/Phase 2 |
| Open-label Study of Surufatinib in Japanese Patients | Hutchison Medipharma Limited | Phase 1/Phase 2 |
| Open-Label Surufatinib in European Patients With NET | Hutchison Medipharma Limited | Phase 2 |
Clinical Trial Summary for Sulfatinib
Top disease conditions for Sulfatinib
Top clinical trial sponsors for Sulfatinib
US Patents for Sulfatinib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Sulfatinib | See Plans and Pricing | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) | See Plans and Pricing |
| Sulfatinib | See Plans and Pricing | Stable, concentrated radionuclide complex solutions | ADVANCED ACCELERATOR APPLICATIONS (ITALY) S.R.L. (Pozzilli (Isernia), IT) | See Plans and Pricing |
| Sulfatinib | See Plans and Pricing | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | Hutchison MediPharma Limited (Shanghai, CN) | See Plans and Pricing |
| Sulfatinib | See Plans and Pricing | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | Hutchison Medipharma Limited (Shanghai, CN) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Sulfatinib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Sulfatinib | Australia | AU2018433575 | 2038-07-25 | See Plans and Pricing |
| Sulfatinib | Brazil | BR112021001148 | 2038-07-25 | See Plans and Pricing |
| Sulfatinib | China | CN112584875 | 2038-07-25 | See Plans and Pricing |
| Sulfatinib | China | CN112867512 | 2038-07-25 | See Plans and Pricing |
| Sulfatinib | China | CN112955188 | 2038-07-25 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
